L2 Cancer Bridge
An immuno-oncology program between Swiss Cancer Center and CREATE Health focused on identifying novel targets for immuno oncology therapy.
Thanks to philanthropic donations to the prestigious Swiss Cancer Center of Lausanne and CREATE Health at Lund University an innovative collaboration was made possible focusing on several aspects of future cancer therapeutic strategies. The donation will support parts of the CREATE Health program, represented by Professors Åke Borg, Thoas Fioretos, Carl Borrebaeck and Kristian Pietras.
The collaboration is divided in two main branches, in which Professors Borg and Pietras collaborate with Professor Douglas Hanahan and Cathrin Brisken in Switzerland in projects related to breast cancer, and Professors Borrebaeck and Fioretos and Dr Lundberg collaborate with Professor George Coukos group in Switzerland in projects related to tumor immunology.
The breast cancer team is focused on studies of tumor cells and their microenvironment with the goal to identify signaling pathways that are
- are crucial for basal-like breast cancer, the most aggressive breast cancer subtype
- block the development of resistance to endocrine therapy.
The tumor immunology team is focused on identifying novel targets on immunoregulatory cells, such as T cells, dendritic cells as various myloid cells. These targets are involved in the immune regulation and can be educated to eradicate tumor cells.